Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Authors :: Langerak AW
Ritgen M
Goede V
Robrecht S
Bahlo J
Fischer K
Steurer M
Trněný M
Mulligan SP
Mey UJM
Trunzer K
Fingerle-Rowson G
Humphrey K
Stilgenbauer S
Böttcher S
Brüggemann M
Hallek M
Kneba M
van Dongen JJM
Source :: Blood [Blood] 2019 Jan 31; Vol. 133 (5), pp. 494-497. Date of Electronic Publication: 2018 Nov 19.
Publication Year :: 2019

Subjects :: Adult
Aged
Aged, 80 and over
Comorbidity
Humans
Leukemia, Lymphocytic, Chronic, B-Cell diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell epidemiology
Middle Aged
Neoplasm, Residual diagnosis
Neoplasm, Residual epidemiology
Prognosis
Prospective Studies
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Chlorambucil therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Neoplasm, Residual drug therapy
Rituximab therapeutic use

Full Text Access

Tools